ASH Annual Meeting and Exposition 2021
ASH Annual Meeting and Exposition 2021
Advertisement
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 3, 2023
The chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) significantly improved event-free ...
Read More
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
According to results from the phase III BELINDA trial, patients with relapsed/refractory aggressive B-cell non-Hodgkin ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated significant and ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
At more than three years of follow-up, most patients with chronic lymphocytic leukemia (CLL) who were treated with a ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
According to the presentation at the 2021 American Society of Hematology Annual Meeting, real-world patients with ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | August 30, 2023
Pivotal trials that supported Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | September 26, 2023
Treatment with the investigational injectable hepcidin mimetic rusfertide effectively controlled levels of hematocrit ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | August 30, 2023
According to results from a phase I/II study, more than 90% of older and high-risk patients with newly diagnosed acute ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 3, 2023
First-line treatment with the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
In a single-arm phase I/II study, infusion with CT103A, a novel fully human B-cell maturation antigen (BCMA)-targeted ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
Chimeric antigen receptor (CAR) T-cell therapy is a potentially life-saving option for patients with hematologic ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
According to results from the phase III BELINDA trial, patients with relapsed/refractory aggressive B-cell non-Hodgkin ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
According to findings from the REGARDS trial, peripheral blood cytopenias may be associated with a higher risk of ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
According to a poster presentation at the 2021 American Society of Hematology, prescribing chemotherapy is not a ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
According to results from the ASCEMBL trial, asciminib was superior to bosutinib in inducing major molecular responses ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
For patients with chronic myeloid leukemia (CML), treatment with tyrosine kinase inhibitors (TKIs) has increased the ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
According to three-year follow-up data from the ASCEND trial, patients with relapsed/refractory chronic lymphocytic ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
Preliminary data from a nonrandomized arm of the SEQUOIA trial, presented at the 2021 Annual Meeting of the American ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
Although individuals older than 80 years make up more than 20% of cases of chronic lymphocytic leukemia (CLL), this ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
According to a study presented at the 2021 American Society of Hematology Annual Meeting, frontline treatment with ...
Advertisement
Advertisement
Advertisement
Latest News

July 16, 2024